Dmitry Malin1, Elena Strekalova, Vladimir Petrovic, Allison M Deal, Abraham Al Ahmad, Barbara Adamo, C Ryan Miller, Andrey Ugolkov, Chad Livasy, Karen Fritchie, Erika Hamilton, Kimberly Blackwell, Joseph Geradts, Matt Ewend, Lisa Carey, Eric V Shusta, Carey K Anders, Vincent L Cryns. 1. Authors' Affiliations: Department of Medicine, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health; Department of Chemical and Biological Engineering, University of Wisconsin, Madison, Wisconsin; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Breast Cancer Unit, Medical Oncology Department, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Center for Developmental Therapeutics, Northwestern University, Evanston, Illinois; Department of Pathology and Lab Medicine, Carolinas Medical Center, Charlotte, North Carolina; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; and Department of Medicine and Department of Pathology, Duke University Medical Center, Durham, North Carolina.
Abstract
PURPOSE: Basal-like breast tumors are typically (ER/PR/HER2) triple-negative and are associated with a high incidence of brain metastases and poor clinical outcomes. The molecular chaperone αB-crystallin is predominantly expressed in triple-negative breast cancer (TNBC) and contributes to an aggressive tumor phenotype in preclinical models. We investigated the potential role of αB-crystallin in brain metastasis in TNBCs. EXPERIMENTAL DESIGN: αB-crystallin expression in primary breast carcinomas and brain metastases was analyzed by immunohistochemistry among patients with breast cancer with brain metastases. αB-crystallin was overexpressed or silenced in two different TNBC cell lines. The effects on cell adhesion to human brain microvascular endothelial cells (HBMEC) or extracellular matrix proteins, transendothelial migration, and transmigration across a HBMEC/astrocyte coculture blood-brain barrier (BBB) model were examined. In addition, the effects of overexpressing or silencing αB-crystallin on brain metastasis in vivo were investigated using orthotopic TNBC models. RESULTS: In a cohort of women with breast cancer brain metastasis, αB-crystallin expression in primary breast carcinomas was associated with poor overall survival and poor survival after brain metastasis, even among patients with TNBC. Stable overexpression of αB-crystallin in TNBC cells enhanced adhesion to HBMECs, transendothelial migration, and BBB transmigration in vitro, whereas silencing αB-crystallin inhibited these events. αB-crystallin promoted adhesion of TNBC cells to HBMECs, at least in part, through an α3β1 integrin-dependent mechanism. αB-crystallin overexpression promoted brain metastasis, whereas silencing αB-crystallin inhibited brain metastasis in orthotopic TNBC models. CONCLUSION: αB-crystallin is a novel regulator of brain metastasis in TNBC and represents a potential biomarker and drug target for this aggressive disease.
PURPOSE: Basal-like breast tumors are typically (ER/PR/HER2) triple-negative and are associated with a high incidence of brain metastases and poor clinical outcomes. The molecular chaperone αB-crystallin is predominantly expressed in triple-negative breast cancer (TNBC) and contributes to an aggressive tumor phenotype in preclinical models. We investigated the potential role of αB-crystallin in brain metastasis in TNBCs. EXPERIMENTAL DESIGN: αB-crystallin expression in primary breast carcinomas and brain metastases was analyzed by immunohistochemistry among patients with breast cancer with brain metastases. αB-crystallin was overexpressed or silenced in two different TNBC cell lines. The effects on cell adhesion to human brain microvascular endothelial cells (HBMEC) or extracellular matrix proteins, transendothelial migration, and transmigration across a HBMEC/astrocyte coculture blood-brain barrier (BBB) model were examined. In addition, the effects of overexpressing or silencing αB-crystallin on brain metastasis in vivo were investigated using orthotopic TNBC models. RESULTS: In a cohort of women with breast cancer brain metastasis, αB-crystallin expression in primary breast carcinomas was associated with poor overall survival and poor survival after brain metastasis, even among patients with TNBC. Stable overexpression of αB-crystallin in TNBC cells enhanced adhesion to HBMECs, transendothelial migration, and BBB transmigration in vitro, whereas silencing αB-crystallin inhibited these events. αB-crystallin promoted adhesion of TNBC cells to HBMECs, at least in part, through an α3β1 integrin-dependent mechanism. αB-crystallin overexpression promoted brain metastasis, whereas silencing αB-crystallin inhibited brain metastasis in orthotopic TNBC models. CONCLUSION: αB-crystallin is a novel regulator of brain metastasis in TNBC and represents a potential biomarker and drug target for this aggressive disease.
Authors: Merideth C Kamradt; Meiling Lu; Michael E Werner; Toni Kwan; Feng Chen; Anne Strohecker; Shayna Oshita; John C Wilkinson; Chunjiang Yu; Patsy G Oliver; Colin S Duckett; Donald J Buchsbaum; Albert F LoBuglio; V Craig Jordan; Vincent L Cryns Journal: J Biol Chem Date: 2005-01-14 Impact factor: 5.157
Authors: T Fujisaki; Y Tanaka; K Fujii; S Mine; K Saito; S Yamada; U Yamashita; T Irimura; S Eto Journal: Cancer Res Date: 1999-09-01 Impact factor: 12.701
Authors: Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes Journal: J Clin Oncol Date: 2006-12-11 Impact factor: 44.544
Authors: Stephanie M Sitterding; William R Wiseman; Carol L Schiller; Chunyan Luan; Feng Chen; Jose V Moyano; William G Watkin; Elizabeth L Wiley; Vincent L Cryns; Leslie K Diaz Journal: Ann Diagn Pathol Date: 2007-10-24 Impact factor: 2.090
Authors: Paula D Bos; Xiang H-F Zhang; Cristina Nadal; Weiping Shu; Roger R Gomis; Don X Nguyen; Andy J Minn; Marc J van de Vijver; William L Gerald; John A Foekens; Joan Massagué Journal: Nature Date: 2009-05-06 Impact factor: 49.962
Authors: Deepak Kanojia; Ramin A Morshed; Lingjiao Zhang; Jason M Miska; Jian Qiao; Julius W Kim; Peter Pytel; Irina V Balyasnikova; Maciej S Lesniak; Atique U Ahmed Journal: Mol Cancer Ther Date: 2015-02-27 Impact factor: 6.261
Authors: Ram H Nagaraj; Rooban B Nahomi; Niklaus H Mueller; Cibin T Raghavan; David A Ammar; J Mark Petrash Journal: Biochim Biophys Acta Date: 2015-04-01
Authors: Elena Strekalova; Dmitry Malin; Erin M M Weisenhorn; Jason D Russell; Dominik Hoelper; Aayushi Jain; Joshua J Coon; Peter W Lewis; Vincent L Cryns Journal: Breast Cancer Res Treat Date: 2019-02-02 Impact factor: 4.872
Authors: Olga Karginova; Marni B Siegel; Amanda E D Van Swearingen; Allison M Deal; Barbara Adamo; Maria J Sambade; Soha Bazyar; Nana Nikolaishvili-Feinberg; Ryan Bash; Sara O'Neal; Katie Sandison; Joel S Parker; Charlene Santos; David Darr; William Zamboni; Yueh Z Lee; C Ryan Miller; Carey K Anders Journal: Mol Cancer Ther Date: 2015-04 Impact factor: 6.261
Authors: Tiffany L Halo; Kaylin M McMahon; Nicholas L Angeloni; Yilin Xu; Wei Wang; Alyssa B Chinen; Dmitry Malin; Elena Strekalova; Vincent L Cryns; Chonghui Cheng; Chad A Mirkin; C Shad Thaxton Journal: Proc Natl Acad Sci U S A Date: 2014-11-17 Impact factor: 11.205